Stock Events

Stock Events

Aptevo Therapeutics 

$1.7000
63
-$0.01-0.58% 09:40 Today

Statistics

Day High
1.735
Day Low
1.6901
52W High
48.78
52W Low
1.37
Volume
22,671
Avg. Volume
-
Mkt Cap
3.08M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-87.8
-59.77
-31.74
-3.72
Expected EPS
-3.715
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-27.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APVO. It's not an investment recommendation.
Amazon
8
AMZN
NVIDIA
8
NVDA
YieldMax MSTR Option Income Strategy
8
MSTY
Apple
7
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Xencor
XNCR
Mkt Cap1.94B
Xencor is involved in developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases, directly competing with Aptevo's antibody-based therapies.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, a cutting-edge area of cancer treatment that competes with Aptevo's innovative approaches to oncology.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes advanced therapies in oncology, directly competing with Aptevo's cancer treatment innovations.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company with a strong focus on antiviral drugs and cancer therapies, making it a competitor in the oncology space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm with a wide range of treatments, including for cancer and inflammatory diseases, competing with Aptevo's therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer treatments that compete with Aptevo's portfolio.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that produces medicines, vaccines, biologic therapies, and animal health products, with a strong presence in the oncology market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical corporation with a diverse portfolio, including oncology treatments that rival Aptevo Therapeutics' offerings.

About

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Show more...
CEO
Jeffrey G. Lamothe
Employees
33
Country
United States
ISIN
US03835L7029
WKN
000A41X00

Listings

MU
DE
AP8N.MU
F
DE
AP82.F
MU
DE
AP82.MU
STU
DE
AP8.STU

0 Comments

Share your thoughts

FAQ

What is Aptevo Therapeutics stock price today?▼
The current price of APVO is $1.70 USD — it has decreased by -0.58% in the past 24 hours. Watch Aptevo Therapeutics stock price performance more closely on the chart.
What is Aptevo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Aptevo Therapeutics stocks are traded under the ticker APVO.
Is Aptevo Therapeutics stock price growing?▼
APVO stock has fallen by -27.7% compared to the previous week, the month change is a -58.19% fall, over the last year Aptevo Therapeutics has showed a -94.17% decrease.
What is Aptevo Therapeutics market cap?▼
Today Aptevo Therapeutics has the market capitalization of 3.08M
When is the next Aptevo Therapeutics earnings date?▼
Aptevo Therapeutics is going to release the next earnings report on November 05, 2026.
What were Aptevo Therapeutics earnings last quarter?▼
APVO earnings for the last quarter are -5.31 USD per share, whereas the estimation was -6.02 USD resulting in a +11.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aptevo Therapeutics revenue for the last year?▼
Aptevo Therapeutics revenue for the last year amounts to 0 USD.
What is Aptevo Therapeutics net income for the last year?▼
APVO net income for the last year is -27.54M USD.
How many employees does Aptevo Therapeutics have?▼
As of September 04, 2026, the company has 33 employees.
In which sector is Aptevo Therapeutics located?▼
Aptevo Therapeutics operates in the Health & Wellness sector.
When did Aptevo Therapeutics complete a stock split?▼
The last stock split for Aptevo Therapeutics was on December 30, 2025 with a ratio of 1:18.
Where is Aptevo Therapeutics headquartered?▼
Aptevo Therapeutics is headquartered in SEATTLE, United States.